These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2526643)

  • 21. Characterization of a human interleukin 1 inhibitor.
    Liao Z; Haimovitz A; Chen Y; Chan J; Rosenstreich DL
    J Immunol; 1985 Jun; 134(6):3882-6. PubMed ID: 3872905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
    Burger D; Chicheportiche R; Giri JG; Dayer JM
    J Clin Invest; 1995 Jul; 96(1):38-41. PubMed ID: 7615809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.
    Seckinger P; Klein-Nulend J; Alander C; Thompson RC; Dayer JM; Raisz LG
    J Immunol; 1990 Dec; 145(12):4181-4. PubMed ID: 2147937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-1 and its receptor.
    Dinarello CA; Savage N
    Crit Rev Immunol; 1989; 9(1):1-20. PubMed ID: 2523282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-4-induced expression of the IL-1 receptor antagonist gene is mediated by STAT6.
    Ohmori Y; Smith MF; Hamilton TA
    J Immunol; 1996 Sep; 157(5):2058-65. PubMed ID: 8757327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of IL-1 activity by soluble IL-1 receptors.
    Kurrle R; Lauffer L; Röder J; Kanzy EJ; Enssle KH; Seiler FR
    Behring Inst Mitt; 1995 Jun; (96):45-57. PubMed ID: 7575352
    [No Abstract]   [Full Text] [Related]  

  • 27. The interleukin-1 receptor antagonist and its delivery by gene transfer.
    Evans CH; Robbins PD
    Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
    Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
    Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia.
    Vogel SN; Henricson BE; Neta R
    Infect Immun; 1991 Jul; 59(7):2494-8. PubMed ID: 1828792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo.
    Faherty DA; Claudy V; Plocinski JM; Kaffka K; Kilian P; Thompson RC; Benjamin WR
    J Immunol; 1992 Feb; 148(3):766-71. PubMed ID: 1530956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.
    Dinarello CA
    Int Rev Immunol; 1998; 16(5-6):457-99. PubMed ID: 9646173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression.
    Pantschenko AG; Pushkar I; Anderson KH; Wang Y; Miller LJ; Kurtzman SH; Barrows G; Kreutzer DL
    Int J Oncol; 2003 Aug; 23(2):269-84. PubMed ID: 12851675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interleukin-1 in pathogenesis of rheumatoid arthritis].
    Iwakura Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():153-7. PubMed ID: 15799336
    [No Abstract]   [Full Text] [Related]  

  • 35. Interleukin-1 and inhibition of interleukin-1 in hemodialysis patients.
    Dinarello CA
    Contrib Nephrol; 1990; 86():48-69; discussion 69-72. PubMed ID: 1706650
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of interleukin-1 receptor antagonist on three types of responses to interleukin-1 in rabbit isolated blood vessels.
    Petitclerc E; Abel S; deBlois D; Poubelle PE; Marceau F
    J Cardiovasc Pharmacol; 1992 May; 19(5):821-9. PubMed ID: 1381781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways.
    Carlson NG; Wieggel WA; Chen J; Bacchi A; Rogers SW; Gahring LC
    J Immunol; 1999 Oct; 163(7):3963-8. PubMed ID: 10490998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-1 and its inhibitors: implications for disease biology and therapy.
    Estrov Z; Kurzrock R; Talpaz M
    Cancer Treat Res; 1995; 80():51-82. PubMed ID: 8821574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interleukin-1 (IL-1), IL-1 receptor, IL-1 receptor antagonist (IL-1ra)].
    Hayashi H; Onozaki K
    Nihon Rinsho; 1999 Nov; 57 Suppl():769-74. PubMed ID: 10635966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.